Celestial Therapeutics Inc.
Celestial Therapeutics is a Johnson & Johnson Innovations - JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.
Celestial Therapeutics Inc.
3210 Merryfield Row San Diego, CA 92121
Celestial Therapeutics Inc. is currently seeking investment
Celestial Therapeutics Inc. is seeking a seed investment in the range of 5m-20m
What We Do
CT-02 is a first-ever broad spectrum dual-modal antiviral & anti-inflammatory therapeutic for treating lung infections due to multiple viruses including, but not limited to, Respiratory Syncytial Virus (RSV), Influenza Virus (IV), and Rhinoviruses (RV), HepC.
A novel self-adjuvanting mRNA vaccine/therapeutics platform that has been validated to significantly enhance efficacy while at the same time, significantly reducing reactogenicity at very low doses, thus making current mRNA vaccines significantly safer and better. Lead mRNA vaccine is for Chikungunya
Vaccines
Digital Health Technologies
Drugs
Key People
Ajay Gupta, Ph.D.
Co-founder, President, Chairman & CEO
Leontis Teryazos, B.A.
Co-founder, Chief Financial Officer, Corporate Secretary & Board Member
George Siber, M.D.
Board Member
George Church, Ph.D.
Scientific Advisor
Sir Michael Houghton, Ph.D., D.Sc. Hon., Nobel Laureate
Scientific Advisor
News & Updates
Dr. George Church, a Professor at Harvard and MIT, has joined Celestial’s Scientific Advisory Board, bringing expertise in genetics and synthetic biology.
Dr. Michael Houghton, a Nobel Prize winner in Physiology or Medicine, has joined Celestial’s Scientific Advisory Board, contributing his expertise in virology and immunology.
Celestial Therapeutics has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California.
Celestial Therapeutics has been accepted into the Mayo Clinic Innovation Exchange to advance its lead dual modal antiviral/anti-inflammatory therapeutic, CT-02, for the treatment of viral myocarditis into human clinical trials.
Celestial Therapeutics has been selected to join the Endless Frontier Labs 2021-2022 cohort alongside 75 ground-breaking companies.
Celestial Therapeutics has been accepted into the StartX community for the Summer 2021 cohort, a prominent technology accelerator in Silicon Valley.